Vivos Therapeutics (VVOS) Debt Ratio (2019 - 2026)

Vivos Therapeutics (VVOS) posted quarterly Debt Ratio of 0.31 for Q1 2026, down 12.14% quarter-over-quarter from 0.35 in Q4 2025.

Vivos Therapeutics (VVOS) Debt Ratio (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has reported Debt Ratio for 5 consecutive years, with 0.31 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.31; the TTM figure through Mar 2026 stood at 0.31 (changed N/A YoY), while the FY2025 annual figure was 0.35, changed N/A from the prior year.
Debt Ratio fell to 0.31 in Q1 2026 per VVOS's latest filing, from 0.35 in the prior quarter.
Across five years, Debt Ratio topped out at 0.35 in Q4 2025 and bottomed at 0.3 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	0.30
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	0.31
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	0.30
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	0.28
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	0.04
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	0.27
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	0.28
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	0.18
10	Vivos Therapeutics	4.94 Mn	3.14 Mn	2.95 Mn	0.34

Download Data